Related Experiment Video
Updated: Sep 4, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP
Muratcan Menteş1, Başak Buse Karakuzulu1, Gönlüm Bahar Uçar1
1Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Abstract:
PI3K pathway is heavily emphasized in cancer where PIK3CA, which encodes for the p110α subunit of PI3Kα, presents itself as the second most common mutated gene. A lot of effort has been put in developing PI3K inhibitors, opening promising avenues for the treatment of cancer. Among these, PI3Kα specific inhibitor alpelisib was approved by FDA for breast cancer and other α-isoform specific inhibitors such as inavolisib and serabelisib reached clinical trials. However, the mode of action of these inhibitors on mutated PI3Kα and how they interact with mutant structures has not been fully elucidated yet. In this study, we are revealing the calculated interactions and binding affinities of these inhibitors within the context of PIK3CA hotspot mutations (E542K, E545K and H1047R) by employing molecular dynamics (MD) simulations. We performed principal component analysis to understand the motions of the protein complex during our simulations and also checked the correlated motions of all amino acids. Binding affinity calculations with MM-PBSA confirmed the consistent binding of alpelisib across mutations and revealed relatively higher affinities for inavolisib towards wild-type and H1047R mutant structures in comparison to other inhibitors. On the other hand, E542K mutation significantly impaired the interaction of inavolisib and serabelisib with PI3Kα. We also investigated the structural relationship of the natural ligand ATP with PI3Kα, and interestingly realized a significant reduction in binding affinity for the mutants, with potentially unexpected implications on the mechanisms that render these mutations oncogenic. Moreover, correlated motions of all residues were generally higher for ATP except the H1047R mutation which exhibited a distinguishable reduction. The results presented here could be guiding for pre-clinical and clinical studies of personalized medicine where individual mutations are a strong consideration point.
Insights
This study investigates PI3K inhibitors targeting PIK3CA mutations in cancer. Alpelisib shows consistent binding, while inavolisib binds strongly to wild-type and H1047R mutants, but E542K impairs binding for inavolisib and serabelisib.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The PI3K pathway is crucial in cancer, with PIK3CA being frequently mutated.
- Development of PI3K inhibitors like alpelisib offers cancer treatment potential.
- The precise interactions of inhibitors with mutated PI3Kα remain unclear.
Purpose of the Study:
- To elucidate the binding interactions and affinities of PI3Kα inhibitors with PIK3CA hotspot mutations.
- To understand the impact of mutations on inhibitor efficacy and natural ligand binding.
- To guide personalized medicine strategies for PIK3CA-mutated cancers.
Main Methods:
- Molecular dynamics (MD) simulations to analyze protein-ligand interactions.
- Principal component analysis (PCA) to study protein complex motions.
- Molecular mechanics with the Poisson-Boltzmann surface area (MM-PBSA) for binding affinity calculations.
Main Results:
- Alpelisib demonstrated consistent binding across all tested PIK3CA mutations.
- Inavolisib exhibited higher binding affinity for wild-type and H1047R PI3Kα.
- The E542K mutation significantly reduced inavolisib and serabelisib binding.
- Mutations decreased the binding affinity of the natural ligand ATP to PI3Kα.
Conclusions:
- Inhibitor efficacy varies significantly with specific PIK3CA mutations.
- PIK3CA mutations may alter the oncogenic mechanism by affecting ATP binding.
- These findings support the development of mutation-specific PI3K inhibitors for personalized cancer therapy.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
13:22Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
ATP Synthase: Mechanism